J. Renger

发表

Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.

John D. Schreier, I. Raheem, J. Fuerst, 2016, Bioorganic & medicinal chemistry letters.

Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis.

G. McGaughey, W. Shipe, J. Uslaner, 2015, Journal of medicinal chemistry.

Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators

Steven V. Fox, J. Uslaner, J. Renger, 2013, Front. Neurosci..

Calcineurin Signaling Mediates Activity-Dependent Relocation of the Axon Initial Segment

M. Evans, J. Renger, M. Grubb, 2013, The Journal of Neuroscience.

A Developmental Switch in Neurotransmitter Flux Enhances Synaptic Efficacy by Affecting AMPA Receptor Activation

Guosong Liu, Christophe Egles, J. Renger, 2001, Neuron.

Essential Thalamic Contribution to Slow Waves of Natural Sleep

V. Crunelli, J. Renger, N. Leresche, 2013, The Journal of Neuroscience.

Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers

D. Dijk, J. Renger, K. Cerchio, 2011, Psychopharmacology.

Trazodone inhibits T-type calcium channels

J. Renger, Yuxing Li, R. Kraus, 2007, Neuropharmacology.

Knocking the NT4 gene into the BDNF locus rescues BDNF deficient mice and reveals distinct NT4 and BDNF activities

R. Jaenisch, J. Renger, R. Klein, 2000, Nature Neuroscience.

Translational Models of Sleep and Sleep Disorders

S. Doran, J. Renger, F. Turek, 2008 .

Targeting of deep-brain structures in nonhuman primates using MR and CT Images

Belma Dogdas, Hatim A. Zariwala, Jason M. Uslaner, 2015, Medical Imaging.

Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.

Steven V. Fox, John D. Schreier, J. Renger, 2014, Bioorganic & medicinal chemistry letters.

Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey

J. Uslaner, J. Renger, S. Kuduk, 2014, Psychopharmacology.

Cross-Modulation and Molecular Interaction at the Cav3.3 Protein between the Endogenous Lipids and the T-Type Calcium Channel Antagonist TTA-A2.

J. Renger, P. Lory, V. Uebele, 2014, Molecular Pharmacology.

New approach for analyzing self-reporting of insomnia symptoms reveals a high rate of comorbid insomnia across a wide spectrum of chronic diseases.

E. Chiauzzi, J. Renger, P. Wicks, 2015, Sleep medicine.

Hypothalamic Neuropeptide S receptor blockade decreases discriminative cue-induced reinstatement of cocaine seeking in the rat

J. Renger, R. Ciccocioppo, V. Uebele, 2012, Psychopharmacology.

Pyroglutamate-Modified Amyloid-β Protein Demonstrates Similar Properties in an Alzheimer's Disease Familial Mutant Knock-In Mouse and Alzheimer's Disease Brain

J. Renger, B. Connolly, M. Savage, 2013, Neurodegenerative Diseases.

Elevation of cytochrome P450-immunopositive protein and DNA damage in mussels (Mytilus edulis) transplanted to a contaminated site.

J. Renger, J. Chipman, D. Livingstone, 2002, Marine environmental research.

A novel link between clusterin and tau pathology in Alzheimer's disease

J. Renger, Katherine Tugusheva, K. Tanis, 2013, Alzheimer's & Dementia.

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain

J. Renger, J. Mudgett, G. Pavlovic, 2010, Journal of Lipid Research.

State-dependent properties of a new T-type calcium channel blocker enhance CaV3.2 selectivity and support analgesic effects

A. Eschalier, D. Ardid, J. Renger, 2013, PAIN.

Orexin receptors in GtoPdb v.2021.3.

J. Siegel, J. Hagan, J. Renger, 2021, IUPHAR/BPS guide to pharmacology CITE.

Orexin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

J. Siegel, J. Hagan, J. Renger, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.

J. Renger, P. Coleman, A. Gotter, 2016, Bioorganic & medicinal chemistry letters.

Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors

J. Renger, P. Coleman, A. Gotter, 2016, Nature Structural &Molecular Biology.

Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.

Steven V. Fox, I. Raheem, J. Renger, 2015, Bioorganic & medicinal chemistry letters.

knockout mice chemoreflex and exaggerated sleep apnea in orexin Vigilance state-dependent attenuation of hypercapnic

J. Renger, P. Coleman, A. Gotter, 2015 .

Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs

Steven V. Fox, J. Uslaner, J. Renger, 2014, Front. Behav. Neurosci..

Discovery of [(2R,5R)‐5‐{[(5‐Fluoropyridin‐2‐yl)oxy]methyl}‐2‐methylpiperidin‐1‐yl][5‐methyl‐2‐(pyrimidin‐2‐yl)phenyl]methanone (MK‐6096): A Dual Orexin Receptor Antagonist with Potent Sleep‐Promoting Properties

Steven V. Fox, John D. Schreier, S. Doran, 2012, ChemMedChem.

Hemodynamic and Cardiac Neurotransmitter-releasing Effects in Conscious Dogs of Attention- and Wake-promoting Agents: A Comparison of d-Amphetamine, Atomoxetine, Modafinil, and a Novel Quinazolinone H3 Inverse Agonist

J. Renger, P. Tannenbaum, C. Regan, 2009, Journal of cardiovascular pharmacology.

Presynaptic CaV3.2 Channels Regulate Excitatory Neurotransmission in Nociceptive Dorsal Horn Neurons

J. Renger, V. Uebele, S. Todorovic, 2012, The Journal of Neuroscience.

Genetic Deletion and Pharmacological Inhibition of PDE10A Protects Mice from Diet-Induced Obesity and Insulin Resistance

Dawn M. Toolan, J. Renger, Sean M. Smith, 2013 .

Orexin 2 receptor regulation of the hypothalamic–pituitary–adrenal (HPA) response to acute and repeated stress

J. Renger, A. Gotter, C. Winrow, 2017, Neuroscience.

Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.

J. Renger, P. Coleman, A. Gotter, 2015, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant.

J. Renger, P. Coleman, A. Gotter, 2014, Bioorganic & medicinal chemistry letters.

Discovery of 3,9-diazabicyclo[4.2.1]nonanes as potent dual orexin receptor antagonists with sleep-promoting activity in the rat.

John D. Schreier, S. Doran, G. McGaughey, 2010, Bioorganic & medicinal chemistry letters.

Discovery of a Potent, CNS‐Penetrant Orexin Receptor Antagonist Based on an N,N‐Disubstituted‐1,4‐diazepane Scaffold that Promotes Sleep in Rats

John D. Schreier, S. Doran, J. Renger, 2009, ChemMedChem.

Proline bis-amides as potent dual orexin receptor antagonists.

J. Renger, P. Coleman, D. Reiss, 2008, Bioorganic & medicinal chemistry letters.

Painful nerve injury decreases sarco-endoplasmic reticulum Ca2+-ATPase activity in axotomized sensory neurons

J. Renger, V. Uebele, H.-e. Wu, 2013, Neuroscience.

Discovery of a Pharmacologically Active Antagonist of the Two‐Pore‐Domain Potassium Channel K2P9.1 (TASK‐3)

Steven V. Fox, S. Doran, J. Renger, 2012, ChemMedChem.

Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.

John D. Schreier, I. Raheem, J. Fuerst, 2012, Bioorganic & medicinal chemistry letters.

The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold

Steven V. Fox, J. Uslaner, J. Renger, 2013, BMC Neuroscience.

GABAergic Synaptic Transmission Triggers Action Potentials in Thalamic Reticular Nucleus Neurons

J. Renger, M. Beierlein, V. Uebele, 2012, The Journal of Neuroscience.

Function, Nomenclature and Pharmacology International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor

L. Velíšek, S. Moshé, J. Renger, 2015 .

State-Dependent Firing Determines Intrinsic Dendritic Ca2+ Signaling in Thalamocortical Neurons

Vincenzo Crunelli, V. Crunelli, J. Renger, 2010, The Journal of Neuroscience.

State-DependentFiringDeterminesIntrinsicDendriticCa 2 SignalinginThalamocorticalNeurons

J. Renger, 2010 .

Control of firing patterns through modulation of axon initial segment T‐type calcium channels

Laurence O Trussell, J. Renger, L. Trussell, 2012, The Journal of physiology.

Uncovering the Genetic Landscape for Multiple Sleep-Wake Traits

Kenneth S. Koblan, Andrew Kasarskis, Fred W. Turek, 2009, PloS one.

Synthesis and evaluation of a new series of Neuropeptide S receptor antagonists.

G. McGaughey, J. Renger, A. Gotter, 2010, Bioorganic & medicinal chemistry letters.

Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists.

Steven V. Fox, James C Barrow, Cuyue Tang, 2010, Bioorganic & medicinal chemistry letters.

Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists.

Steven V. Fox, S. Doran, G. McGaughey, 2010, ACS medicinal chemistry letters.

Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.

John D. Schreier, S. Doran, G. McGaughey, 2010, Journal of medicinal chemistry.

Activity-dependent Functional and Developmental Plasticity of Drosophila Neurons

J. Renger, Chun-Fang Wu, J. E. Engel, 1998 .

Experience-dependent plasticity without long-term depression by type 2 metabotropic glutamate receptors in developing visual cortex

T. Hensch, S. Nakanishi, J. Renger, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Identification and in Vivo Evaluation of Liver X Receptor β-Selective Agonists for the Potential Treatment of Alzheimer's Disease.

K. K. Nanda, M. Rudd, J. Uslaner, 2016, Journal of medicinal chemistry.

Improved stability of Drosophila larval neuromuscular preparations in haemolymph-like physiological solutions

J. Renger, H. Atwood, Chun-Fang Wu, 1994, Journal of Comparative Physiology A.

Discovery and development of orexin receptor antagonists as therapeutics for insomnia

J. Renger, C. Winrow, 2014, British journal of pharmacology.

OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2‐INDUCED PANIC‐ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES

P. Bonaventure, J. Renger, C. Winrow, 2015, Depression and anxiety.

Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia

Steven V. Fox, John D. Schreier, J. Renger, 2014, ChemMedChem.

Orexin signaling during social defeat stress influences subsequent social interaction behaviour and recognition memory

J. Renger, A. Gotter, C. Winrow, 2019, Behavioural Brain Research.

Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding.

G. McGaughey, J. Renger, P. Coleman, 2009, Bioorganic & medicinal chemistry letters.

In Vitro Characterization of T-Type Calcium Channel Antagonist TTA-A2 and In Vivo Effects on Arousal in Mice

Steven V. Fox, S. Doran, J. Renger, 2010, Journal of Pharmacology and Experimental Therapeutics.

Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells

J. Renger, Lihang Yao, N. Hatcher, 2015, The Journal of Neuroscience.

Presynaptic HCN1 channels regulate CaV3.2 activity and neurotransmission at select cortical synapses

J. Renger, R. Luján, A. Dolphin, 2011, Nature Neuroscience.

Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice.

S. Doran, J. Renger, J. Barrow, 2009, The Journal of clinical investigation.

Identification of causal genes, networks, and transcriptional regulators of REM sleep and wake.

A. Kasarskis, Bin Zhang, E. Schadt, 2011, Sleep.

Pre-synaptic HCN1 channels regulate excitatory neurotransmission at select cortical synapses by altering CaV3.2 Ca2+ channel activity

J. Renger, R. Luján, A. Dolphin, 2011, Nature neuroscience.

Neuronal Polymorphism among Natural Alleles of a cGMP-Dependent Kinase Gene, foraging, in Drosophila

J. Renger, M. Sokolowski, W. Yao, 1999, The Journal of Neuroscience.

TASK-3 as a potential antidepressant target

Steven V. Fox, H. Meziane, S. Doran, 2011, Brain Research.

Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.

Steven V. Fox, S. Doran, W. Shipe, 2008, Journal of medicinal chemistry.

Regulation of Gene Expression by Lithium and Depletion of Inositol in Slices of Adult Rat Cortex

Robert L. Phillips, M. Parrish, A. Simon, 2005, Neuron.

Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition

Steven V. Fox, Xiaohai Wang, Jason M. Uslaner, 2013, Science Translational Medicine.

Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man

Steven V. Fox, J. Renger, P. Coleman, 2016, Scientific Reports.

Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators

Steven V. Fox, J. Uslaner, J. Renger, 2014, BMC Neuroscience.

Quantitative Electroencephalography Within Sleep/Wake States Differentiates GABAA Modulators Eszopiclone and Zolpidem From Dual Orexin Receptor Antagonists in Rats

Steven V. Fox, J. Uslaner, J. Renger, 2013, Neuropsychopharmacology.

Orexin receptors as therapeutic drug targets.

J. Renger, P. Coleman, A. Gotter, 2012, Progress in brain research.

Intracellular Clusterin Interacts with Brain Isoforms of the Bridging Integrator 1 and with the Microtubule-Associated Protein Tau in Alzheimer's Disease

J. Renger, Katherine Tugusheva, I. Hayashi, 2014, PloS one.

Refined anatomical isolation of functional sleep circuits exhibits distinctive regional and circadian gene transcriptional profiles

Kenneth S. Koblan, John J. Renger, M. Marton, 2009, Brain Research.

Blood-gene expression reveals reduced circadian rhythmicity in individuals resistant to sleep deprivation.

A. Podtelezhnikov, D. Stone, A. Pack, 2014, Sleep.

T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats

Jason M. Uslaner, John J. Renger, Victor N. Uebele, 2012, Neuropharmacology.

Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist

Steven V. Fox, S. Doran, J. Renger, 2011, Journal of neurogenetics.

Pyridyl amides as potent inhibitors of T-type calcium channels.

Steven V. Fox, S. Doran, G. McGaughey, 2011, Bioorganic & medicinal chemistry letters.

A Sensitive Aβ Oligomer Assay Discriminates Alzheimer's and Aged Control Cerebrospinal Fluid

J. Renger, Katherine Tugusheva, N. Hatcher, 2014, The Journal of Neuroscience.

High throughput monitoring of amyloid-β(42) assembly into soluble oligomers achieved by sensitive conformation state-dependent immunoassays.

Dawn M. Toolan, J. Renger, Wei⁃qin Zhao, 2011, Journal of Alzheimer's disease : JAD.

Cross-species systems analysis identifies gene networks differentially altered by sleep loss and depression

Andrew Kasarskis, Joshua Millstein, Joseph R. Scarpa, 2018, Science Advances.

Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia

Steven V. Fox, John D. Schreier, S. Doran, 2012, Neuropharmacology.

Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-β peptides in the cerebral spinal fluid of rats

J. Renger, C. Zerbinatti, S. A. Villarreal, 2010, Molecular Neurodegeneration.

Hypothalamic Neuropeptide S receptor blockade decreases discriminative cue-induced reinstatement of cocaine seeking in the rat

J. Renger, R. Ciccocioppo, V. Uebele, 2013, Psychopharmacology.

Tricyclic imidazole antagonists of the Neuropeptide S Receptor.

K. K. Nanda, J. Renger, A. Gotter, 2010, Bioorganic & medicinal chemistry letters.

Biphasic Cholinergic Synaptic Transmission Controls Action Potential Activity in Thalamic Reticular Nucleus Neurons

Juan D. Pita-Almenar, J. Renger, M. Beierlein, 2013, The Journal of Neuroscience.

Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease

J. Uslaner, J. Renger, B. Connolly, 2017, Neurobiology of Aging.

Transcriptional Profiling of Cholinergic Neurons From Basal Forebrain Identifies Changes in Expression of Genes Between Sleep and Wake

A. Podtelezhnikov, D. Stone, A. Pack, 2017, Sleep.

Nerve Terminal Nicotinic Acetylcholine Receptors Initiate Quantal GABA Release from Perisomatic Interneurons by Activating Axonal T-Type (Cav3) Ca2+ Channels and Ca2+ Release from Stores

Daniel A. Nagode, J. Renger, M. Klugmann, 2011, The Journal of Neuroscience.

Minimal alterations in T‐type calcium channel gating markedly modify physiological firing dynamics

R C Lambert, T. Bal, J. Renger, 2011, The Journal of physiology.

Selective T-Type Calcium Channel Block in Thalamic Neurons Reveals Channel Redundancy and Physiological Impact of ITwindow

Hee-Sup Shin, Vincenzo Crunelli, V. Crunelli, 2010, The Journal of Neuroscience.

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

J. Krystal, C. Correll, J. Renger, 2022, The Lancet.

T-type calcium channels regulate cortical plasticity in-vivo NR-D-08-7049

Sara J. Aton, J. Renger, J. Barrow, 2009, Neuroreport.

Rebound excitation triggered by synaptic inhibition in cerebellar nuclear neurons is suppressed by selective T-type calcium channel block.

Rebecca Boehme, J. Renger, C. Pedroarena, 2011, Journal of neurophysiology.

Role of cAMP Cascade in Synaptic Stability and Plasticity: Ultrastructural and Physiological Analyses of Individual Synaptic Boutons in Drosophila Memory Mutants

C. Govind, J. Renger, H. Atwood, 2000, The Journal of Neuroscience.

Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist.

Steven V. Fox, S. Doran, W. Shipe, 2008, Journal of medicinal chemistry.

The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.

J. Renger, P. Coleman, A. Gotter, 2017, Annual review of pharmacology and toxicology.

Evaluation of automated and semi-automated scoring of polysomnographic recordings from a clinical trial using zolpidem in the treatment of insomnia.

Junshui Ma, Vladimir Svetnik, S. Doran, 2007, Sleep.

Pharmacological Validation of Candidate Causal Sleep Genes Identified in an N2 Cross

Steven V. Fox, A. Kasarskis, J. Renger, 2011, Journal of neurogenetics.

Selective orexin 2 receptor antagonism blocks cue-induced reinstatement, but not nicotine self-administration or nicotine-induced reinstatement

J. Uslaner, J. Renger, P. Coleman, 2014, Behavioural Brain Research.

Acute Alertness‐Promoting Effects of a Novel Histamine Subtype‐3 Receptor Inverse Agonist in Healthy Sleep‐Deprived Male Volunteers

J. Renger, K. Cerchio, R. Iannone, 2010, Clinical pharmacology and therapeutics.

Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents.

Steven V. Fox, S. Doran, W. Zeng, 2010, ACS medicinal chemistry letters.

Orexin receptor antagonists: a review of promising compounds patented since 2006

J. Renger, P. Coleman, Paul J Coleman, 2010, Expert opinion on therapeutic patents.

International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology

J. Renger, P. Coleman, A. Gotter, 2012, Pharmacological Reviews.

Genetic Deletion and Pharmacological Inhibition of Phosphodiesterase 10A Protects Mice From Diet-Induced Obesity and Insulin Resistance

Dawn M. Toolan, I. Raheem, J. Renger, 2013, Diabetes.

Inhibition of T-type calcium current in rat thalamocortical neurons by isoflurane

J. Renger, V. Uebele, S. Todorovic, 2012, Neuropharmacology.

Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure

Steven V. Fox, Kenneth S. Koblan, Jason M. Uslaner, 2010, Neuropharmacology.

Altered sleep and affect in the neurotensin receptor 1 knockout mouse.

A. Kasarskis, J. Renger, A. Gotter, 2012, Sleep.

Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey

J. Uslaner, J. Renger, S. Kuduk, 2015, Psychopharmacology.

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.

Marc Poirier, Michael W. Miller, Christian Mirescu, 2017, Journal of medicinal chemistry.

Evidence for orexinergic mechanisms in migraine

J. Renger, C. Winrow, P. Goadsby, 2015, Neurobiology of Disease.

Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors.

I. Raheem, L. Gantert, E. Hostetler, 2015, Bioorganic & medicinal chemistry letters.

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey

Dawn M. Toolan, John D. Schreier, I. Raheem, 2013, Neuropharmacology.

Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).

J. Renger, P. Coleman, S. Garson, 2013, Bioorganic & medicinal chemistry letters.

PCSK 9 is not involved in the degradation of LDL receptors and BACE 1 in the adult mouse brain

J. Renger, J. Mudgett, G. Pavlovic, 2010 .

The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents

Dawn M. Toolan, Monika Kandebo, J. Uslaner, 2015, Neuropharmacology.

The dual orexin receptor antagonist, DORA‐22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine

Steven V. Fox, J. Uslaner, J. Renger, 2017, Journal of neurochemistry.

Early‐stage comparative effectiveness: Randomized controlled trial with histamine inverse agonist MK‐7288 in excessive daytime sleepiness patients

C. Lines, J. Renger, G. Kay, 2013, Journal of clinical pharmacology.

Histamine H3 inverse agonist PET tracers labelled with carbon-11 or fluorine-18

S. Doran, L. Gantert, J. Renger, 2008, NeuroImage.

ApoE4 confers better spatial memory than apoE3 in young adult hAPP-Yac/apoE-TR mice

J. Renger, C. Kelche, C. Mathis, 2013, Behavioural Brain Research.

A novel multivalent Abeta peptide vaccine with preclinical evidence of a central immune response that generates antisera recognizing a wide range of Abeta peptide species

J. Renger, A. McCampbell, M. Citron, 2010, Alzheimer's & Dementia.

Sub-chronic administration of zolpidem affects modifications to rat sleep architecture

J. Renger, S. Motzel, K. Koblan, 2004, Brain Research.

A New Class of Hypnotic Compounds for the Treatment of Insomnia: The Dual Orexin Receptor Antagonists

J. Uslaner, J. Renger, P. Coleman, 2015 .

Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.

J. Renger, H. Su, Hemaka A. Rajapakse, 2016, Bioorganic & medicinal chemistry letters.

T-Type Calcium Channels Consolidate Tonic Action Potential Output of Thalamic Neurons to Neocortex

Hee-Sup Shin, Thierry Bal, John J. Renger, 2012, The Journal of Neuroscience.

Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans

Sabrina Fox‐Bosetti, C. Lines, P. Maruff, 2011, Psychopharmacology.

Automated Sleep Scoring with Human Supervision Adds Value Compared with Human Scoring Alone: A reply to Zammit G. K. Insufficient evidence for the use of automated and semi-automated scoring of polysomnographic recordings. SLEEP 2008:31;449–50.

S. Doran, J. Renger, V. Svetnik, 2008 .

Positive Allosteric Interaction of Structurally Diverse T-Type Calcium Channel Antagonists

Steven V. Fox, S. Doran, J. Renger, 2009, Cell Biochemistry and Biophysics.

Role of voltage-gated calcium channels in potassium-stimulated aldosterone secretion from rat adrenal zona glomerulosa cells

J. Renger, V. Uebele, T. Connolly, 2004, The Journal of Steroid Biochemistry and Molecular Biology.

Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists.

D. Stone, J. Renger, S. Duvvuri, 2021, The Journal of clinical investigation.

Quantitative Proteomics in Laser Capture Microdissected Sleep Nuclei From Rat Brain

Daniel S Spellman, J. Renger, P. Coleman, 2014, Journal of neurogenetics.

Preface to the Special Issue “Novel Pharmaconeurogenetic Approaches Arising from Progress in Translational Genetics”

John J. Renger, Jonathan T. Kern, J. Renger, 2011, Journal of neurogenetics.

Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain

J. Renger, P. Coleman, K. Smith, 2016, Journal of neurogenetics.

Future Needs in Issue Resolution of Problems That Arise in Drug Development

Michael K. Pugsley, Matthew M. Abernathy, Tiffany Montevideo Whitney, 2019, Advanced Issue Resolution in Safety Pharmacology.

11C-MK-8278 PET as a Tool for Pharmacodynamic Brain Occupancy of Histamine 3 Receptor Inverse Agonists

Sandra M. Sanabria-Bohórquez, G. Bormans, J. Renger, 2014, The Journal of Nuclear Medicine.

A Comparative Study on the Lysosomal Cation Channel TMEM175 Using Automated Whole-Cell Patch-Clamp, Lysosomal Patch-Clamp, and Solid Supported Membrane-Based Electrophysiology: Functional Characterization and High-Throughput Screening Assay Development

D. Stone, J. Renger, N. Fertig, 2023, International journal of molecular sciences.

REDUCED CIRCADIAN RHYTHMICITY IN INDIVIDUALS RESISTANT TO SLEEP DEPRIVATION Blood-Gene Expression Reveals Reduced Circadian Rhythmicity in Individuals Resistant to Sleep Deprivation

A. Podtelezhnikov, J. Renger, C. Winrow, 2014 .

Essential Thalamic Contribution to Slow Waves of Natural Sleep

V. Crunelli, J. Renger, N. Leresche, 2013, The Journal of Neuroscience.

Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.

John D. Schreier, I. Raheem, J. Fuerst, 2012, Bioorganic & medicinal chemistry letters.

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain

J. Renger, J. Mudgett, G. Pavlovic, 2010, Journal of Lipid Research.

State-dependent properties of a new T-type calcium channel blocker enhance CaV3.2 selectivity and support analgesic effects

A. Eschalier, D. Ardid, J. Renger, 2013, PAIN.

EARLY CLINICAL RESULTS AND PRECLINICAL VALIDATION OF THE O-GLCNACASE (OGA) INHIBITOR MK-8719 AS A NOVEL THERAPEUTIC FOR THE TREATMENT OF TAUOPATHIES

Dawn M. Toolan, Joseph James Duffy, J. Renger, 2016, Alzheimer's & Dementia.

Discovery and development of orexin receptor antagonists as therapeutics for insomnia

J. Renger, C. Winrow, 2014, British journal of pharmacology.

Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys.

Steven V. Fox, J. Uslaner, J. Renger, 2016, Sleep.

New approach for analyzing self-reporting of insomnia symptoms reveals a high rate of comorbid insomnia across a wide spectrum of chronic diseases.

E. Chiauzzi, J. Renger, P. Wicks, 2015, Sleep medicine.

Early‐stage comparative effectiveness: Randomized controlled trial with histamine inverse agonist MK‐7288 in excessive daytime sleepiness patients

C. Lines, J. Renger, G. Kay, 2013, Journal of clinical pharmacology.

Discovery of a Pharmacologically Active Antagonist of the Two‐Pore‐Domain Potassium Channel K2P9.1 (TASK‐3)

Steven V. Fox, S. Doran, J. Renger, 2012, ChemMedChem.

Pre-synaptic HCN1 channels regulate excitatory neurotransmission at select cortical synapses by altering CaV3.2 Ca2+ channel activity

J. Renger, R. Luján, A. Dolphin, 2011, Nature Neuroscience.

J. Renger, P. Tannenbaum, C. Regan, 2009, Journal of Cardiovascular Pharmacology.

T-Type Calcium Channel Antagonism Decreases Motivation for Nicotine and Blocks Nicotine- and Cue-Induced Reinstatement for a Response Previously Reinforced with Nicotine

J. Uslaner, J. Renger, V. Uebele, 2010, Biological Psychiatry.

ApoE4 confers better spatial memory than apoE3 in young adult hAPP-Yac/apoE-TR mice

J. Renger, C. Kelche, C. Mathis, 2013, Behavioural Brain Research.

The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol

J. Renger, R. Zoethout, R. Schoemaker, 2012, Journal of Psychopharmacology.